Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer.
about
Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology.Soluble E-cadherin: more than a symptom of disease.Abnormal expression of serum soluble E-cadherin is correlated with clinicopathological features and prognosis of breast cancer.Expression of E-cadherin, N-cadherin and snail and their correlation with clinicopathological variants: an immunohistochemical study of 132 invasive ductal breast carcinomas in Egypt.ADAM15 Is Functionally Associated with the Metastatic Progression of Human Bladder CancerThe effects of 1,4-dimethylpyridine in metastatic prostate cancer in miceRUNX2 and TAZ-dependent signaling pathways regulate soluble E-Cadherin levels and tumorsphere formation in breast cancer cells.Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion frontCleavage of transmembrane junction proteins and their role in regulating epithelial homeostasis.Methodology and applications of disease biomarker identification in human serum.Emerging biomarkers of prostate cancer (Review)Beyond a tumor suppressor: Soluble E-cadherin promotes the progression of cancer.Formation of intracellular lumina in human prostate carcinoma (DU145) cells, maturation into signet cells, and the cribriform morphology of tumors.Xenotransplanted human prostate carcinoma (DU145) cells develop into carcinomas and cribriform carcinomas: ultrastructural aspects.EGF promotes the shedding of soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells.Suppression of migration and invasion of PC3 prostate cancer cell line via activating E-cadherin expression by small activating RNA.Beta-catenin mediates alteration in cell proliferation, motility and invasion of prostate cancer cells by differential expression of E-cadherin and protein kinase D1.Roles of RUNX in Hippo Pathway Signaling.
P2860
Q33605010-0EBB766A-4A41-4F46-982F-686E3BFA5616Q34279705-7CF9BBBC-CF3C-493D-B03B-19B3C9FBE7E6Q34789523-04683872-F9C6-43C4-B8AB-4E03F8E1D58AQ35232419-416D59FC-844D-438D-859C-D8F1713DC0C7Q35941467-EF3EF482-903D-47CE-BBF0-E9F8688D8F42Q36300102-93662C53-58C4-47C5-8F40-3BEE4D760295Q36413997-36FA5A34-A97C-494B-A598-D2F739C7A2C8Q36848899-442F6A20-8B83-4F3D-9AD3-28DB428AC7D0Q37428089-B02CEEDD-F2B5-4698-97B2-A9E29CCF897AQ37574961-40C5CA59-D024-479C-A04E-B26E3FE9414CQ38013967-4E1E3BAB-69CF-4E9B-BF12-DE01E3294A20Q38679713-9B3F58DC-6BED-4737-B68D-C3845CA57B2EQ38780754-2E99F2D8-85EB-493C-9684-9A612954988AQ39268465-E9BFB3E0-7A94-454C-B6EE-B18AEFA42F94Q39453489-F8AA7FFD-AB5D-463A-93B7-33CFCB529BF4Q39670420-8747A1B7-2327-4D79-AD2B-546A3C45051BQ40057893-29DD2C97-1682-4345-A6C6-72D54C87D6B5Q47944350-3A5B39CF-0463-4E3E-BD1B-0B00D48E10B0
P2860
Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Assessment of a fragment of e- ...... ive value for prostate cancer.
@ast
Assessment of a fragment of e- ...... ive value for prostate cancer.
@en
type
label
Assessment of a fragment of e- ...... ive value for prostate cancer.
@ast
Assessment of a fragment of e- ...... ive value for prostate cancer.
@en
prefLabel
Assessment of a fragment of e- ...... ive value for prostate cancer.
@ast
Assessment of a fragment of e- ...... ive value for prostate cancer.
@en
P2093
P2860
P356
P1476
Assessment of a fragment of e- ...... tive value for prostate cancer
@en
P2093
B G Volkmer
C S M Zorn
J E Gschwend
M A Juarez-Brito
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602599
P407
P50
P577
2005-06-01T00:00:00Z